Novo Nordisk shares are up 7% premarket today. The FDA signaled they plan to crack down on companies mass-marketing unapproved copycat drugs, specifically targeting quality concerns. This is helping the stock recover from a steep drop earlier this week. The sell-off started when Hims & Hers launched a $49 compounded version of Wegovy and Novo released a weak forecast for 2026. Management expects sales and profits to fall in 2026 due to competition and patent expirations, but the FDA comments are providing a bounce.